SG10201914137YA - Methods and compositions for rna-guided treatment of hiv infection - Google Patents

Methods and compositions for rna-guided treatment of hiv infection

Info

Publication number
SG10201914137YA
SG10201914137YA SG10201914137YA SG10201914137YA SG10201914137YA SG 10201914137Y A SG10201914137Y A SG 10201914137YA SG 10201914137Y A SG10201914137Y A SG 10201914137YA SG 10201914137Y A SG10201914137Y A SG 10201914137YA SG 10201914137Y A SG10201914137Y A SG 10201914137YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
rna
hiv infection
guided treatment
Prior art date
Application number
SG10201914137YA
Inventor
Kamel Khalili
Wenhui Hu
Yonggang Zhang
Original Assignee
Univ Temple
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple filed Critical Univ Temple
Publication of SG10201914137YA publication Critical patent/SG10201914137YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION Compositions for specifically cleaving target sequences in retroviruses include nucleic acids encoding a Clustered Regularly Interspace Short Palindromic Repeat (CRISPR) associated endonuclease and a guide RNA sequence complementary to one or more target nucleic acid sequences in a retrovirus genome. [No suitable figure]
SG10201914137YA 2015-06-01 2016-06-01 Methods and compositions for rna-guided treatment of hiv infection SG10201914137YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169384P 2015-06-01 2015-06-01
US201562169633P 2015-06-02 2015-06-02
US201662308320P 2016-03-15 2016-03-15

Publications (1)

Publication Number Publication Date
SG10201914137YA true SG10201914137YA (en) 2020-02-27

Family

ID=57442165

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201914137YA SG10201914137YA (en) 2015-06-01 2016-06-01 Methods and compositions for rna-guided treatment of hiv infection

Country Status (16)

Country Link
US (3) US11298410B2 (en)
EP (2) EP3919622A1 (en)
JP (1) JP6968416B2 (en)
KR (2) KR102553518B1 (en)
CN (1) CN108025188A (en)
AU (2) AU2016270702B2 (en)
CA (1) CA2987927C (en)
DK (1) DK3302709T3 (en)
EA (1) EA037359B1 (en)
ES (1) ES2886480T3 (en)
HK (1) HK1253882A1 (en)
MX (1) MX2017015582A (en)
PL (1) PL3302709T3 (en)
SG (1) SG10201914137YA (en)
WO (1) WO2016196539A2 (en)
ZA (1) ZA201708236B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (en) 2011-07-22 2020-04-22 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9068179B1 (en) 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
KR102553518B1 (en) * 2015-06-01 2023-07-07 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Methods and compositions for RNA-guided treatment of HIV infection
JP2018527943A (en) * 2015-09-28 2018-09-27 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Methods and compositions for the treatment of RNA-induced HIV infection
CN108513575A (en) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 Nucleobase editing machine and application thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (en) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Aav delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
JP2020510439A (en) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ Base-editing factor from cytosine to guanine
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US20200140865A1 (en) * 2017-04-17 2020-05-07 Temple University - Of The Commonwealth System Of Higher Education An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11788088B2 (en) * 2017-09-26 2023-10-17 The Board Of Trustees Of The University Of Illinois CRISPR/Cas system and method for genome editing and modulating transcription
CN111757937A (en) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 Use of adenosine base editor
WO2020150499A1 (en) * 2019-01-16 2020-07-23 Fred Hutchinson Cancer Research Center Methods to tag and isolate cells infected with the human immunodeficiency virus
DE112020001342T5 (en) 2019-03-19 2022-01-13 President and Fellows of Harvard College Methods and compositions for editing nucleotide sequences
US20210147862A1 (en) * 2019-10-23 2021-05-20 Pairwise Plants Services, Inc. Compositions and methods for rna-templated editing in plants
EP4114952A4 (en) * 2020-03-05 2024-05-08 Board of Regents of the University of Nebraska Crispr/cas9 system for multistrain hiv-1 treatment
EP4146804A1 (en) 2020-05-08 2023-03-15 The Broad Institute Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN112322587A (en) * 2020-09-17 2021-02-05 杭州市第一人民医院 Human-derived inducible pluripotent stem cell line with Cas9 gene, construction method, identification method and application

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US11274305B2 (en) 2013-04-04 2022-03-15 Trustees Of Dartmouth College Compositions and methods for in vivo excision of HIV-1 proviral DNA
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
CN103923911B (en) 2014-04-14 2016-06-08 上海金卫生物技术有限公司 The method of CRISPR-Cas9 specific knockdown CCR5 gene and the sgRNA for selectively targeted CCR5 gene
CN104480144B (en) 2014-12-12 2017-04-12 武汉大学 CRISPR/Cas9 recombinant lentiviral vector for human immunodeficiency virus gene therapy and lentivirus of CRISPR/Cas9 recombinant lentiviral vector
KR102553518B1 (en) 2015-06-01 2023-07-07 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Methods and compositions for RNA-guided treatment of HIV infection
JP2018527943A (en) 2015-09-28 2018-09-27 テンプル ユニバーシティー オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション Methods and compositions for the treatment of RNA-induced HIV infection
EP3362104A4 (en) 2015-10-16 2019-03-27 Temple University - Of The Commonwealth System of Higher Education Methods and compositions utilizing cpf1 for rna-guided gene editing
AU2016366229A1 (en) 2015-12-09 2018-05-17 Excision Biotherapeutics, Inc. Gene editing methods and compositions for eliminating risk of JC virus activation and PML (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
US9925425B2 (en) 2016-03-17 2018-03-27 Acushnet Company Golf ball incorporating at least three adjacent ionomeric and/or HNP-based layers having multiple related property gradients there between
US20190093091A1 (en) 2016-04-06 2019-03-28 Temple University - Of The Commonwealth System Of Higher Education Compositions for eradicating flavivirus infections in subjects
WO2017192172A1 (en) 2016-05-05 2017-11-09 Temple University - Of The Commonwealth System Of Higher Education Rna guided eradication of varicella zoster virus
WO2017213898A2 (en) 2016-06-07 2017-12-14 Temple University - Of The Commonwealth System Of Higher Education Rna guided compositions for preventing and treating hepatitis b virus infections
US20190085326A1 (en) 2016-09-14 2019-03-21 Temple University - Of The Commonwealth System Of Higher Education Negative feedback regulation of HIV-1 by gene editing strategy
WO2018071623A2 (en) 2016-10-12 2018-04-19 Temple University - Of The Commonwealth System Of Higher Education Combination therapies for eradicating flavivirus infections in subjects
US11535568B2 (en) 2016-11-30 2022-12-27 Hrl Laboratories, Llc Monomer formulations and methods for 3D printing of preceramic polymers
JP2020505390A (en) 2017-01-26 2020-02-20 エクシジョン バイオセラピューティクス インコーポレイテッド Lentiviruses and non-integrating lentiviruses as viral vectors for delivering CRISPR therapeutics
WO2018152418A1 (en) 2017-02-17 2018-08-23 Temple University - Of The Commonwealth System Of Higher Education Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5
US20200140865A1 (en) 2017-04-17 2020-05-07 Temple University - Of The Commonwealth System Of Higher Education An hiv-1 eradication strategy employing nanoformulated anti-retroviral drugs and gene editing agents

Also Published As

Publication number Publication date
US20210052709A1 (en) 2021-02-25
MX2017015582A (en) 2018-09-06
WO2016196539A2 (en) 2016-12-08
KR102553518B1 (en) 2023-07-07
AU2016270702A1 (en) 2017-12-21
PL3302709T3 (en) 2021-12-06
ZA201708236B (en) 2019-12-18
KR20230110368A (en) 2023-07-21
EP3302709A4 (en) 2019-01-23
US11298410B2 (en) 2022-04-12
EP3302709B1 (en) 2021-05-19
US20180296649A1 (en) 2018-10-18
AU2022201875A1 (en) 2022-04-07
EA201890012A1 (en) 2018-05-31
KR20180023911A (en) 2018-03-07
US11273209B2 (en) 2022-03-15
DK3302709T3 (en) 2021-08-23
EP3919622A1 (en) 2021-12-08
EP3302709A2 (en) 2018-04-11
CA2987927C (en) 2024-03-19
EA037359B1 (en) 2021-03-17
JP6968416B2 (en) 2021-11-17
ES2886480T3 (en) 2021-12-20
US20200282025A1 (en) 2020-09-10
CA2987927A1 (en) 2016-12-08
WO2016196539A3 (en) 2017-02-16
AU2016270702B2 (en) 2022-01-20
JP2018516572A (en) 2018-06-28
CN108025188A (en) 2018-05-11
HK1253882A1 (en) 2019-07-05

Similar Documents

Publication Publication Date Title
SG10201914137YA (en) Methods and compositions for rna-guided treatment of hiv infection
WO2017058658A3 (en) Methods and compositions for rna-guided treatment of hiv infection
MX2016002586A (en) Methods and compositions for rna-guided treatment of hiv infection.
WO2017213898A3 (en) Rna guided compositions for preventing and treating hepatitis b virus infections
WO2017100431A3 (en) Gene editing methods and compositions for eliminating risk of jc virus activation and pml (progressive multifocal leukoencephalopathy) during immunosuppresive therapy
RU2022103603A (en) NUCLEIC ACID-DIRECTED NUCLEASE
MX2022006603A (en) Broad spectrum influenza virus vaccine.
WO2019006471A3 (en) Novel crispr rna targeting enzymes and systems and uses thereof
AU2011257555A8 (en) Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
WO2016183402A3 (en) Methods of making and using guide rna for use with cas9 systems
RU2016104056A (en) MULTIPLEX GENOMIC ENGINEERING DIRECTED BY RNA
EP4349404A3 (en) Respiratory virus vaccines
MX2020011939A (en) Novel crispr enzymes and systems.
WO2018071623A3 (en) Combination therapies for eradicating flavivirus infections in subjects
MX2017005672A (en) Rna guided eradication of man jc virus and other polyomaviruses.
WO2016086177A3 (en) Compositions and methods for hiv quasi-species excision from hiv-1-infected patients
MX2018005392A (en) Engineered nucleic-acid targeting nucleic acids.
SG10201908773UA (en) Tat-induced crispr/endonuclease-based gene editing
WO2015200555A3 (en) Rna modification to engineer cas9 activity
WO2016100955A3 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
MX2016011686A (en) Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency.
MX2019006475A (en) SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA.
MD20170014A2 (en) Methods for the treatment of hepatitis B and hepatitis D virus infections
WO2015042308A3 (en) Rna-based hiv inhibitors
CA3153995A1 (en) Mad7 nuclease in plants and expanding its pam recognition capability